Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dermapharm Holding SECHIX:DMPD 80 Cash-to-Debt is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 5,016.51. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €43.89. The stock has 5 warning signs investors should review. Among 983 Drug Manufacturers companies, Dermapharm Holding SE ranks worse than 74.57% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Dermapharm Holding SE's cash to debt ratio for the quarter that ended in Mar. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Dermapharm Holding SEcould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Dermapharm Holding SE's Cash-to-Debt or its related term are showing as below:
CHIX:DMPd'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 5016.51 Max: No Debt
Current: 0.24
During the past 13 years, Dermapharm Holding SE's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 5016.51.
CHIX:DMPd's Cash-to-Debt is ranked worse than 74.57% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs CHIX:DMPd: 0.24
Dermapharm Holding SE (CHIX:DMPd) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Dermapharm Holding SE Cash-to-Debt Related Terms
Dermapharm Holding SE Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Cash-to-Debt falls into.
Dermapharm Holding SE's Cash to Debt Ratio for the quarter that ended in Mar. 2026 is calculated as:
Dermapharm Holding SE had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Dermapharm Holding SE (CHIX:DMPD) has a Cash-to-Debt of No Debt (1) as of Mar. 2026. This is 100% below median its historical median of 5,016.51. Over the past decade, Dermapharm Holding SE's Cash-to-Debt has ranged from 0.02 to 10,000.00. According to the industry distribution chart, Dermapharm Holding SE ranks #733 out of 983 companies in the Drug Manufacturers industry, placing it in the top 74.6%.
Is Dermapharm Holding SE's Cash-to-Debt too high?
Dermapharm Holding SE's current Cash-to-Debt of No Debt (1) is 100% below median its 10-year median of 5,016.51. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 10,000.00. Based on the distribution chart, Dermapharm Holding SE ranks #733 out of 983 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #733 out of 983 companies for Cash-to-Debt. This places Dermapharm Holding SE in the lower half of its industry. The industry median Cash-to-Debt is 0.98. Historically, Dermapharm Holding SE's own Cash-to-Debt has ranged from 0.02 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current Cash-to-Debt is No Debt (1), which is 100% below median its own 10-year median of 5,016.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Cash-to-Debt of No Debt (1). The stock's GF Value™ is €43.89, compared to a current price of €46.18 — trading 5.2% above its estimated fair value. The current Cash-to-Debt is No Debt (1), which is 100% below median its 10-year median of 5,016.51. Dermapharm Holding SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Cash-to-Debt is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 5.2% above its estimated GF Value™ of €43.89.
Key valuation signals for CHIX:DMPD:
Cash-to-Debt: No Debt (1) (100% below median its 10-year median of 5,016.51)
GF Value™: €43.89 vs. price of €46.18 (5.2% above fair value)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
